Breast Cancer Research and Treatment

, Volume 88, Issue 1, pp 1–8

Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids

  • M. Kusama
  • K. Miyauchi
  • H. Aoyama
  • M. Sano
  • M. Kimura
  • S. Mitsuyama
  • K. Komaki
  • H. Doihara


This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a multicenter randomized comparative study between April 1997 and March 2001. As adjuvant therapy, 20 mg of TAM or 40 mg of TOR was administered for 1 year. The levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-1 (Apo A-1), apolipoprotein A(Apo B), and lipoprotein a (Lp(a)) were measured prior to administration and 3, 6, and 12 months after the start of administration. TC, LDL-C, Lp(a) and Apo B significantly decreased from the third month of administration compared with values before the start of administration in both the TOR and TAM groups. HDL-C significantly increased from the third month only in the TOR group. TG significantly increased in the TAM group but significantly decreased in the TOR group in the 12th month of administration. When these two groups were compared, HDL-C was significantly higher ( p < 0.01) and TG was significantly lower ( p < 0.01) in the TOR group in the 12th month. Improvement of abnormal values of TG, HDL-C and LDL-C was better in the TOR group than in the TAM group after administration for 12 months. The effect on lipid metabolism showed different profiles between the two selective estrogen receptor modulators (SERMs), and TOR gave better results than TAM.

adjuvant therapy high-density lipoprotein cholesterol low-density lipoprotein cholesterol postmenopausal breast cancer SERMs serum lipid tamoxifen toremifene total cholesterol triglyceride 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mouridsen HT, Palshof T: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5:131–141, 1978Google Scholar
  2. 2.
    Early Breast Cancer Trialists 'Collaborative Group: Tamoxifen for early breast cancer:an overview of the randomized trials. Lancet 351:1451–1467, 1998Google Scholar
  3. 3.
    Love RR, Wiebe DA, Feyzi JM, Newcom PA, Chappel RJ: Effects of tamoxifen on cardiovascular risk factors in postmenopausal woman after 5 years of treatment. J Natl Cancer Inst 86:1534–1539, 1994Google Scholar
  4. 4.
    Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O: Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrineol Metab 83:1158–1162, 1998Google Scholar
  5. 5.
    Kangas L, Kallio S, Blanco G, Gronroos M, Kallio S, Karjalaninen A, Perila M, Sodervall M, Toivola R: A new triphenylethylene compound,FC-1157a:Antitumor effect. Cancer Chemother Pharmacol 17:109–114, 1986Google Scholar
  6. 6.
    Pyrhonen S, Ellmen J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M, Hayes DF: Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.Breast Cancer Res Treat 56:133–143, 1999Google Scholar
  7. 7.
    Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, Pukkala E, Joensuu H: Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. J Clin Oncol 18:3487–3494, 2000Google Scholar
  8. 8.
    Saarto T, Blomqvist C, Ehnholm C, Taskinen M-R, Elomaa I: Antiaetherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and tremifen on plasma lipid levels in post-menopausal woman with node-positive breast cancer. J Clin Oncol 14: 429–433, 1996Google Scholar
  9. 9.
    Riggs BL, Hartmann LC: Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348: 618–629, 2003Google Scholar
  10. 10.
    Japan AtherosclerosisSociety: Japan Atherosclerosis Society (JAS)Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases. Japan Atherosclerosis Society Publications,2002, pp.3–5Google Scholar
  11. 11.
    Gordon T, Casteli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707–714, 1977Google Scholar
  12. 12.
    Arca M, Vega GL, Grundy SM: Hypercholesterolemia in post-menopausal woman. Metabolic defects and response to low-dose lovastin. JAMA 271: 453–459, 1994Google Scholar
  13. 13.
    Jonat W, Kaufmann M, Sauebrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin. Oncol 20: 4628–4635, 2002Google Scholar
  14. 14.
    Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G: Relation of serum lipoprotein(a)concentration and apolipoprotein(a)phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 322: 1494–1499, 1990Google Scholar
  15. 15.
    Kannel WB: Serum cholesterol,lipoproteons,and risk of coronary heart disease,the Framingham study. Ann Intern Med 74: 1–12, 1971Google Scholar
  16. 16.
    Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D: Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet ii: 933–936, 1986Google Scholar
  17. 17.
    Matsuzawa Y, Tarui S: Recent trend in the research of hyperlipidemia in Japan (1). Profiles of primary hyperlipidemia. Nihon Naika Gakkai Zasshi 78(10): 1396–1399, 1989Google Scholar
  18. 18.
    Stein JH, Rosenson RS: Lipoprotein LP(a)excess and coronary heart disease. Arch Intern Med 157: 1170–1176, 1997Google Scholar
  19. 19.
    Austin MA, King MC, Vranizan KM: Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. Am J Hum Genet 43: 838–846, 1988Google Scholar
  20. 20.
    Nigon F, Lesnik P, Rouis M: Discrete are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 32: 1741–1753, 1991Google Scholar
  21. 21.
    Tribble FC, Holl LG, Wood PD: Variations inoxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93: 189–199, 1992Google Scholar
  22. 22.
    Grodstein F, Stampfer MJ, Colditz GA, Wilett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE: Postmenopausal hormone therapy and mortality. N Engl J Med 336: 1769–1775, 1997Google Scholar
  23. 23.
    Hulley S, Grady D, Bush T, Furgerg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal woman. Heart and Estrogen/Progestin Replacement Study (HERS) Reaserch Group. JAMA 280: 605–613, 1998Google Scholar
  24. 24.
    Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB: Estrogen and progestin,lipoprotein(a),and the risk of recurrent coronary heart disease events after menopause. JAMA 283: 1845–1852, 2000Google Scholar
  25. 25.
    Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Water D: Effects of estrogen replacement on the progression of coronary–artery atherosclerosis. N Eng J Med 343: 522–529, 2000Google Scholar
  26. 26.
    Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345: 1243–1249, 2001Google Scholar
  27. 27.
    Writing Group for the Woman 's Health Initiative Investigators Risk and benefits of estrogen plus progestin in healthy postmenopausal woman: principal results from the Woman 's Health Initiative randomized controlled trial. JAMA 288: 321–333, 2002Google Scholar
  28. 28.
    Kalkhoven E, Valentine JE, Heery DM, Parker MG: Isoform of steroid receptor co-activator 1 differ in their ability to potentiate by the oestrogen receptor. EMBO J 17: 232–243, 1998Google Scholar
  29. 29.
    Schwartz JA, Liu G, Brooks SC: Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes. Biochem Biophys Res Commun 253: 38–43, 1998Google Scholar
  30. 30.
    Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP: American Society of Clinical Oncology Assessment on the use of aromatase inhibitors as adjuvant for woman with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 20: 3317–3327, 2002Google Scholar
  31. 31.
    McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J 303: 435–437, 1991Google Scholar
  32. 32.
    Rutquist LE, Mattsson: A Cardiac and thromboembolic morbidity among postmenopausal woman with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85: 1398–1406, 1993Google Scholar
  33. 33.
    Joensuu H, Holli K, Oksanen H, Valavaara R: Serum lipid level during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 63: 22–234 2000Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • M. Kusama
    • 1
  • K. Miyauchi
    • 2
  • H. Aoyama
    • 3
  • M. Sano
    • 4
  • M. Kimura
    • 5
  • S. Mitsuyama
    • 6
  • K. Komaki
    • 7
  • H. Doihara
    • 8
  1. 1.Third Department of SurgeryTokyo Medical UniversityJapan
  2. 2.Miyauchi ClinicJapan
  3. 3.Nagoya National HospitalJapan
  4. 4.Niigata Cancer CenterJapan
  5. 5.Gunma Cancer CenterJapan
  6. 6.Kitakyusyu Municipal Medical CenterJapan
  7. 7.School of MedicineUniversity of TokushimaJapan
  8. 8.Okayama University Medical SchoolJapan

Personalised recommendations